This webinar features lawyers from Sidley’s Private Equity, Emerging Companies and Venture Capital, and Food, Drug and Medical Device Regulatory teams in conversation with leaders from Jefferies Group addressing the recent surge in biotech-related SPAC transactions. We explore:
- The state of the current SPAC market
- Critical considerations for a biotech target
- Common pitfalls when executing a SPAC transaction
- How the de-SPAC differs from traditional exits
- SPACs’ impact on biotech financing
SPEAKERS
Josh G. DuClos
Partner, Private Equity, Sidley
Charlie Glazer
Managing Director, Head of Healthcare ECM, Jefferies
Geoffrey W. Levin
Partner, Private Equity, Sidley
Diane C. McEnroe
Partner, Food, Drug and Medical Device Regulatory, Sidley
Frank Rahmani
Partner, Emerging Companies and Venture Capital, Sidley
For more information or questions, please email GlobalLifeSci@sidley.com.
ABOUT THE SERIES
This webinar series is designed to discuss topics relevant to private equity investors in life sciences and healthcare. Sessions have covered the boom in telehealth, securing the drug supply chain, FDA approvals in the time of COVID and opportunities for investing in animal health in an evolving regulatory landscape.
